About 64x Bio

64x Bio develops a high throughput genome engineering platform that accelerates the discovery of optimized mammalian cell lines for cell and gene therapies. This technology enables pharmaceutical and biotechnology companies to efficiently design and manufacture next-generation therapeutics, addressing the challenges of traditional cell line development.

```xml <problem> Developing optimized mammalian cell lines for cell and gene therapies is a time-consuming and challenging process. Traditional cell line development methods often struggle to efficiently produce cell lines with the specific characteristics required for next-generation therapeutics. </problem> <solution> 64x Bio offers a high-throughput genome engineering platform designed to accelerate the discovery and optimization of mammalian cell lines. This platform combines novel genome engineering techniques with computational tools in a design loop, enabling the generation of highly optimized cell lines that may be unattainable through conventional methods. By enhancing the design and manufacturing process, 64x Bio's technology aims to help pharmaceutical and biotechnology companies more effectively bring cell and gene therapies to patients. The platform is specifically focused on cell lines used in the production of cell and gene therapies. </solution> <features> - High-throughput genome engineering for rapid cell line modification. - Computational tools integrated into a design loop for iterative optimization. - Focus on mammalian cell lines used in cell and gene therapies. - Platform designed to improve the efficiency of cell line development. </features> <target_audience> The primary customers are pharmaceutical and biotechnology companies, as well as Contract Development and Manufacturing Organizations (CDMOs), involved in the development and manufacturing of cell and gene therapies. </target_audience> ```

What does 64x Bio do?

Where is 64x Bio located?

64x Bio is based in San Francisco, United States.

When was 64x Bio founded?

64x Bio was founded in 2017.

How much funding has 64x Bio raised?

64x Bio has raised $59.5M.

Who founded 64x Bio?

64x Bio was founded by Kingsley Advani, Farhad (Seyyedhassan) Paylakhi and Lexi Rovner.

Kingsley Advani - Founder/CEO
Farhad (Seyyedhassan) Paylakhi - Co-Founder, Vice President R&D
Lexi Rovner - Co-Founder/CEO

64x Bio

San Francisco, United StatesFounded 2017243K+ followers10/10 TractionRelative Traction Score based on online presence metrics compared to companies in the same age group.

Updated 19 months ago

Funding

$59.5M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.

Funding rounds are not available yet.

Founders

Product

Problem

Developing optimized mammalian cell lines for cell and gene therapies is a time-consuming and challenging process. Traditional cell line development methods often struggle to efficiently produce cell lines with the specific characteristics required for next-generation therapeutics.

Solution

64x Bio offers a high-throughput genome engineering platform designed to accelerate the discovery and optimization of mammalian cell lines. This platform combines novel genome engineering techniques with computational tools in a design loop, enabling the generation of highly optimized cell lines that may be unattainable through conventional methods. By enhancing the design and manufacturing process, 64x Bio's technology aims to help pharmaceutical and biotechnology companies more effectively bring cell and gene therapies to patients. The platform is specifically focused on cell lines used in the production of cell and gene therapies.

Target Audience

The primary customers are pharmaceutical and biotechnology companies, as well as Contract Development and Manufacturing Organizations (CDMOs), involved in the development and manufacturing of cell and gene therapies.

Features

High-throughput genome engineering for rapid cell line modification.
Computational tools integrated into a design loop for iterative optimization.
Focus on mammalian cell lines used in cell and gene therapies.
Platform designed to improve the efficiency of cell line development.